Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED).

Full DD Report for OMED

You must become a subscriber to view this report.


Recent News from (NASDAQ: OMED)

Compugen, 'From Code To Cure': Becoming A Clinical-Stage Company
With a market cap of only $225 million (including $43 million in cash as of June 30th), Compugen Ltd. ( CGEN ) has the potential to deliver outsized returns for shareholders over the next 12 to 24 months. Since publishing my initial article on Compugen on SA on February 20, 2018, Compugen ...
Source: SeekingAlpha
Date: September, 05 2018 10:11
OncoMed to Present at Two Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Offic...
Source: GlobeNewswire
Date: August, 29 2018 16:00
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
-Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018- -Cash runway extended by an additional quarter to YE 2019- REDWOOD CITY, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a ...
Source: GlobeNewswire
Date: August, 02 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-071.010.98011.03460.87011,468,556
2018-12-061.161.021.161.00543,980
2018-12-041.151.11011.19641.10104,413
2018-12-031.171.141.251.12180,010
2018-11-301.271.171.291.17167,793

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07221,308696,30331.7833Cover
2018-12-0669,575191,30836.3681Short
2018-12-0416,58942,88738.6807Short
2018-12-0331,26368,45645.6688Short
2018-11-3023,30149,12947.4282Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OMED.


About OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED)

Logo for OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: OMED)

      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: August, 21 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 02 2018
      Amendment to a previously filed 8-K
      Filing Type: 8-K/AFiling Source: edgar
      Filing Date: June, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 25 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: June, 19 2018
      Correspondence from the Filer to the SEC
      Filing Type: CORRESPFiling Source: edgar
      Filing Date: June, 18 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: June, 13 2018
      Correspondence from the SEC to the Filer
      Filing Type: UPLOADFiling Source: edgar
      Filing Date: June, 08 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 25 2018

       

       


      Daily Technical Chart for (NASDAQ: OMED)

      Daily Technical Chart for (NASDAQ: OMED)


      Stay tuned for daily updates and more on (NASDAQ: OMED)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: OMED)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OMED is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OMED and does not buy, sell, or trade any shares of OMED. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/